Table 2.
Main characteristics of all studies included in the meta-analysis for disease-free survival.
| First Author (pub year) | Patients Ki-67 or MIB1 ± (total) | Median FU (mos) | Antibody | Test method | Threshold (chosen by) | HR (95% CI) |
|---|---|---|---|---|---|---|
| Bahnassy AA (2006) | 38 | 13 (mean) | NR | IHC | NR | 1.38 (0.66–2.87) |
| Graflund M 1 N+ (2002) | 37 | 222 (mean) | MIB-1 | IHC | 1% (PI) | 0.30 (0.10–0.91) |
| Graflund M 2 N+ (2002) | 37 | 222 (mean) | MIB-1 | IHC | 1% (PI) | 0.28 (0.01–0.85) |
| Klimek M (2011) | 122 | 5y | Anti-Ki-67 | IHC | 52% (PI) | 1.19 (1.05–3.50) |
| Morimura Y (1998) | 34 | NR | Anti-MIB-1 | IHC | 25% (PI) | 1.86 (0.20–17.82) |
| Nakano T (1993) | 45 | 3y (minimum) | Anti-Ki-67 | IHC | 33% (PMI) | 0.8 (0.06–12.05) |
| Oka K (2000) | 75 | NR | Anti-MIB-1 | IHC | 40% (PI) | 4.88 (0.42–55.98) |
| Yang M (2014) | 180 | 64 (mean) | Anti-Ki-67 | IHC | 10% (PI) | 3.80 (2.50–4.90) |
HR – hazard ratio; CI – confidence interval; N+ – node-positive; NR – not reported; + – positive; ‘−’ – negative; y – years; PI – proliferation index; PMI – mitotic index of proliferating cell population.